Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter.
EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25.
For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively.
Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26.
Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).
The scrip declined 1.09% to end at Rs 564.95 on the BSE.
Granules Pharmaceuticals, Inc., a wholly owned subsidiary of Granules India, has received Tentative Approval (TA) from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Amphetamine Extended-Release Tablets in strengths of 5 mg, 10 mg, 15 mg, and 20 mg, the generic equivalent of DYANAVEL XR®.
The Granules ANDA has been determined to be eligible for 180-day exclusivity by the FDA, reinforcing its growing capabilities in developing and commercializing complex and differentiated generic products for the U.S. market. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and has an estimated market size of approximately USD 41 million.
Granules previously received a tentative approval on December 22nd, 2025 for Amphetamine Extended Release Orally Disintegrating Tablets in strengths of 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, and 18.8 mg, the generic equivalent of ADZENYS XR-ODT® also for the treatment of ADHD. This product has only one approved generic and one authorized generic with an addressable market share of USD 172 million, positioning Granules favourably to expand access to this critical therapy upon launch. The tentative approval of generic gDYANAVEL XR tablets marks the second consecutive approval from Granules' subsidiary, Granules Pharmaceuticals, Inc., within a period of a few weeks.
Earlier, on 22 December 2025, Granules Pharmaceuticals received tentative approval for Amphetamine Extended-Release Orally Disintegrating Tablets in multiple strengths, the generic equivalent of ADZENYS XR-ODT, also used for the treatment of ADHD. This product currently has only one approved generic and one authorized generic, with an addressable market of about $172 million.
The company said the tentative approval for generic DYANAVEL XR tablets marks the second consecutive approval for Granules Pharmaceuticals within a few weeks, highlighting its growing capabilities in complex formulation development and regulatory execution.
Dr. Krishna Prasad Chigurupati, chairman & managing director, Granules India, said, “Having a product that is eligible for 180-day exclusivity, Granules strongly validates our long-term strategy of building a differentiated portfolio of complex generics. It also reinforces our commitment to strengthening our presence in the central nervous system (CNS) therapeutic space while enhancing value creation in the U.S. generics market.”
The company’s consolidated net profit declined 16.3% to Rs 112.64 crore, while net sales increased 3.4% to Rs 1,208.79 crore in Q2 FY26 compared with Q2 FY25.
Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India, has received Tentative Approval (TA) from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Amphetamine Extended-Release Orally Disintegrating Tablets in strengths of 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, and 18.8 mg, the generic equivalent of ADZENYS XR-ODT®. It will be manufactured at Granules' US-based facility located in Chantilly, Virginia.
The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and has an estimated market size of approximately USD 172 million according to IQVIA (IMS Health).
Currently, the market has only one approved generic and one authorised generic, positioning Granules favourably to expand access to this critical therapy upon launch.
Currently, the market has only one approved generic and one authorised generic, giving Granules a favourable position to expand access to this therapy upon launch.
The company said the tentative approval strengthens its US generics portfolio and underscores its continued investments in complex dosage forms, patient-friendly delivery technologies, and value-driven healthcare solutions.
Dr Krishna Prasad Chigurupati, chairman and managing director, stated, “The tentative approval of this ANDA reaffirms Granules’ strategic focus on expanding its portfolio of complex and differentiated generics while strengthening its presence in the central nervous system (CNS) therapeutic area. ADHD is one of the most commonly diagnosed neurodevelopmental disorders in the United States and impacts hundreds of millions of people worldwide. At Granules, we remain committed to improving patient access by delivering high-quality, affordable medications across global markets.”
The counter rose 0.25% to Rs 584.75 on the BSE.
The inspection was conducted at the subsidiary's Hyderabad facility between 15 December and 19 December 2025. The regulator issued five observations, all related to procedural requirements.
The company said none of the observations pertain to data integrity or product safety. Granules India added that it will respond to the observations within the stipulated timeframe.
Granules Life Sciences is engaged in the manufacturing of pharmaceutical formulation intermediates and finished dosage forms.
Shares of Granules India rose 0.50% to settle at Rs 583.30 on Friday, 19 December 2025.